Coexistence of primary myelofibrosis and chronic lymphocytic leukemia

References

• Burgstaller S, Wimmer S, Mayrbaeurl B, et al. Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent. Blood Cancer J. 2011;1:e20.
   Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute – Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate analysis. Cancer. 1981;48:198–204.
   PubMed Web of Science ®Google Scholar
• Rai KR. A critical analysis of staging in CLL. In: Gale RP, Rai KR, editors. Chronic Lymphocytic Leukemia: Recent Progress and Future Directions. New York, NY, USA: Liss; 1987.
   Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL):results of a randomized Phase III trial on behalf of an international group of investigators and the German CLL Study Group. Lancet. 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27: 4378–4384.
   PubMed Web of Science ®Google Scholar
• Gribben JG, O’Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011;29:544–550.
   PubMed Web of Science ®Google Scholar
• Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26:5094–5100.
   PubMed Web of Science ®Google Scholar
• Gonzales-Rodriguez AP, Payer AR, Acebes-Huerto A, et al. Lenalidomide and chronic lymphocytic leukemia. BioMed Res Int. 2013;932010.
   Web of Science ®Google Scholar
• Berg JW. The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma. J Natl Cancer Inst. 1967;38:741–752.
   PubMed Web of Science ®Google Scholar
• Hyman GA. Increased incidence of neoplasia in association with chronic lymphocytic leukaemia. Scand J Haematol. 1969;6:99–104.
   Google Scholar
• Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol. 1998;25:27–33.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008;83:491–497.
   PubMed Web of Science ®Google Scholar
• Vanucchi AM. Management of myelofibrosis. Hematology Am Soc Hematol Educ Program. 2011;2011:222–230.
   Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392–397.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic scoring model to predict survival in primary myelofibrosis – a study by the IWG-MRT (International Working Group for Myelofibrosis Research and Treatment). Blood. 2010;116:1703–1708.
   Google Scholar
• McLornan DP, Mead AJ, Jackson G, Harrison CN. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol. 2012;157: 413–425.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofibrosis. Cancer J. 2007;13:377–383.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108:1158–1164.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27: 4760–4766.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Yao X, Cripe LD, et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase-2 trial E4903. Blood. 2010;116:4436–4438.
   PubMed Web of Science ®Google Scholar
• Daver N, Shastri A, Kadia T, et al. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res. 2013;37: 1140–1444.
   Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352: 1779–1790.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7: 387–397.
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366: 799–807.
   PubMed Web of Science ®Google Scholar
• Böhm J, Schaefer HE, Fisch P. [Coincidence of chronic idiopathic myelofibrosis and chronic lymphocytic leukemia. A rare phenomenon]. Pathologe. 2002;23:480–485. German.
   Web of Science ®Google Scholar
• Nieto LH, Sanchez JMR, Arguelles HA, et al. A case of chronic lymphocytic leukemia overwhelmed by rapidly progressing idiopathic myelofibrosis. Haematologica. 2000;85:973–977.
   PubMed Web of Science ®Google Scholar
• Kaufman S, Iuclea S, Reif R. Idiopathic myelofibrosis complicated by chronic lymphocytic leukemia. Clin Lab Haematol. 1987;9:81–84.
   PubMedGoogle Scholar
• Zylberait D, Audebert AA, Grolleau Y, et al. Association de leucémie lymphoide chronique et de splénomégalie myéloide. A propos de deux observations [Two cases of agnogenic myeloid metaplasia associated with chronic lymphocytic leukemia]. Nouv Rev Fr Hematol. 1981;23:111–113. French.
   PubMedGoogle Scholar
• Guerci O, Floquet J, Thibaut G, et al. Splénomégalie myéloide avec lymphopathie maligne. Ann Med Nancy. 1978;12:187–189. French.
   Google Scholar
• Louwagie AC, Desmet VJ, van den Berghe H. Coexistence of a myelo- and lymphoproliferative disorder. Scand J Haematol. 1973;11: 350–355.
   PubMedGoogle Scholar
• Videbaek A, Poulsen H. Myelofibrosis complicated by lymphogenous leukaemia. Acta Haematol. 1957;17:250–256.
   Google Scholar
• Palta A, Garg S, Chauhan S, et al. Simultaneous presence of two haematological malignancies: chronic lymphocytic leukemia and myelofibrosis in a patient. Indian J Hematol Blood Transfus. 2011;27:33–34.
   Web of Science ®Google Scholar
• Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86: 1007–1012.
   PubMed Web of Science ®Google Scholar
• Papayannis AG, Nikiforakis E, Aanagnostou-Keramida D. Devolpment of chronic lymphocytic leukemia in a patient with polycythemia vera. Scand J Haematol. 1982;29:65–69.
   PubMedGoogle Scholar
• Carulli G, Marini A, Baicchi U, et al. Chronic lymphocytic leukemia (B-cell) in the course of polycythemia vera. Description of a case with an unusual chromosomic anomaly. Tumori. 1987;73:639–643.
   PubMed Web of Science ®Google Scholar
• Mautes E, Morilla R, Farahat N, et al. Definition of acute biphenotypic leukemia. Haematologica. 1989;82:64–66.
   Google Scholar